Evox Therapeutics, a leading exosome therapeutics company, today announced that the Company has been granted four new patents covering a broad range of exosome manufacturing methods and processes. Evox has been granted US Patent US11,298,319, European patents EP3700566 and EP3569254, and Japanese Patent JP6999601.
Taken together these four patents, in three key jurisdictions, provide broad protection for a large range of downstream purification as well as methods of exogenous drug cargo loading which are routinely used by all companies operating in the exosome field.
Specifically, the claims cover a method of purifying engineered exosomes via a downstream process utilizing ultrafiltration and size-based separation steps, an affinity chromatography process, and two methods of loading exosomes with a wide range of pharmacological agents including oligonucleotides and small molecules.
“These newly issued patents stand testament to the great work our scientists and engineers are performing every day, to continuously innovate and improve our proprietary DeliverEX™ technology platform, in order to develop commercially viable and regulatory compliant methods and manufacturing processes to support industrialization of exosome therapeutics,” said Peter Jones, Vice President CMC at Evox.
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, added, “We are very pleased to add these four patents to Evox’s growing IP estate. Together these broad patents protect some of the key manufacturing elements, which are widely used in the field of exosome therapeutics. These grants highlight Evox’s dominant position in the exosome field. The Evox patent portfolio now contains 81 granted patents, 17 of which are in these 3 key jurisdictions. This represents the most comprehensive intellectual property portfolio in the field and is a testament to the ground-breaking work of our founders and Evox scientists and the excellence of our intellectual property team.”
Source – Globe Newswire